The MiR-200c/FOXP3 Network: A Promising Biomarker for Predicting Trastuzumab Response in HER2-Positive Breast Cancer
Loading...
Date
2023-10
Journal Title
Journal ISSN
Volume Title
Type
Article
Publisher
Sage: Technology in Cancer Research & Treatment
Series Info
2 Technology in Cancer Research & Treatment; Volume 23: 1-10
Scientific Journal Rankings
Abstract
Purpose: Resistance to Trastuzumab is a significant challenge in the management of HER2-positive Metastatic Breast cancer
(HER2-MBC), and a better understanding of the molecular causes of resistance is required to develop more effective treatment
plans. While elevated plasma levels of miR-200 and FOXP3 have been linked to breast cancer progression and treatment
response, no clinical studies have confirmed these results. Methods: The study involved 40 patients with HER2-positive metastatic
breast cancer (HER2-MBC). The expression levels of miR-200c-3p and the FOXP3 gene were assessed in plasma samples at
two time points: baseline (BL) and after the consent completion of one cycle of Trastuzumab, utilizing quantitative polymerase
chain reaction (qPCR). Clinical response to Trastuzumab was evaluated 12 months post-therapy and correlated with the time to
progression (TTP) through Kaplan-Meier analysis. Results: Low plasma expression level of miR-200c-3p was detected before
therapy in HER2-MBC, compared to healthy controls, and decreased dramatically in the follow-up sample at disease progression,
while increased after one cycle of Trastuzumab therapy in patients who were sensitive to Trastuzumab. At baseline, a low expression
level of miR-200c was significantly associated with overexpression of FOXP3, poor prognosis, and shorter time to progression.
Conclusions: The findings suggest that miR-200c-3p may be a promising biomarker for predicting the response to
Trastuzumab in HER2-MBC patients.
Description
miRNA, micro-RNA; HER2-MBC, HER2-positive Metastatic Breast cancer; BC, breast cancer; BL, baseline; 1C, after completing
Trastuzumab treatment; FOXP3, forkhead box P3; HER2, human epidermal growth factor receptor 2; TTP, time to progression;
STROBE, Strengthening the Reporting of Observational Studies in Epidemiology; PASS, Power Analysis and Sample Size Software;
ROC, Receiving operating characteristics curve; CI, 95% confidence interval; AUC, area under the curve.
Keywords
Trastuzumab, HER2-positive breast cancer, metastatic breast cancer, drug resistance, miR-200c, FOXP3, predictor biomarker